Skip to main content

Table 4 Intention-to-treat analysis of changes in prescribing rates showing sum scores per clinical topic and scores per drug

From: Effect of audit and feedback with peer review on general practitioners’ prescribing and test ordering performance: a cluster-randomized controlled trial

  Intervention Control     
Clinical topic n Mean before (sd) Mean after (sd) n Mean before (sd) Mean after (sd) Ba (95% CI) icc Direction p
Anaemia
 Iron preparations, oral 39 25.0 (20.7) 45.1 (40.0) 49 27.4 (28.4) 49.2 (55.7) 3.9 (−13.9, 21.5) 0.21 = 0.644
Urinary tract infections
 Antibiotics UTI 39 43.5 (31.6) 47.3 (36.5) 49 47.5 (38.7) 59.7 (48.7) 11.9 (−3.2, 27.0) 0.21 0.113
 Prostate complaints 39 59.1 (43.3) 107.1 (69.6) 49 66.5 (58.6) 127.5 (102.2) 20.0 (−20.9, 60.8) 0.38 0.306
 Alpha receptor blockers 39 49.6 (35.7) 86.6 (56.2) 49 55.0 (49.5) 103.3 (81.5) 18.5 (−15.3, 52.3) 0.42 0.258
 5 alpha reductase inhibitors 39 9.5 (9.5) 20.4 (18.6) 49 11.5 (11.2) 24.2 (24.7) 1.4 (−7.2, 10.0) 0.01 0.735
 Stomach complaints 49 329.7 (286.9) 612.0 (477.0) 39 282.6 (210.1) 491.8 (333.4) 106.7 (−70.7, 284.2) 0.63 0.219
 H2 antagonists 49 27.8 (26.4) 32.4 (30.0) 39 22.3 (20.5) 21.3 (16.4) 12.5 (−1.8, 26.8) 0.44 0.081
 Proton pump inhibitors 49 300.8 (262.9) 578.3 (452.3) 39 259.4 (192.3) 469.1 (322.1) 93.7 (−71.9, 259.4) 0.62 0.246
 Misoprostol 49 0.1 (0.4) 0.0 (0.2) 39 0.1 (0.4) 0.2 (0.5) −0.1 (−0.2,−0.0) 0.00 0.008 b
 Triple therapy (ATC A02BD04) 49 1.0 (1.7) 1.3 (2.0) 39 0.9 (1.3) 1.1 (1.7) 0.2 (−0.7, 1.2) 0.49 0.593 b
 Thyroid dysfunction 49 81.3 (66.3) 137.2 (102.6) 39 71.4 (48.9) 107.1 (71.6) 21.2 (−14.1, 56.6) 0.42 = 0.217
 Thyroid hormones 49 74.8 (60.8) 125.0 (92.6) 39 66.9 (47.4) 100.8 (70.0) 18.2 (−16.0, 52.4) 0.45 = 0.269
 Antithyroid preparations 49 6.5 (8.6) 12.2 (17.8) 39 4.5 (4.4) 6.3 (7.3) 2.6 (−1.7, 7.0) 0.09 0.218 b
 Perimenopausal complaints 49 56.4 (42.7) 56.8 (41.8) 39 46.3 (34.2) 46.0 (29.6) 6.6 (−12.0, 25.2) 0.56 0.459
 Oestrogens, oral 49 14.1 (13.6) 12.7 (12.1) 39 12.3 (11.8) 11.2 (10.4) 0.2 (−3.6, 4.1) 0.01 0.889
 Contraceptives (>50y) 49 3.6 (3.2) 6.4 (4.9) 39 3.2 (3.9) 5.9 (4.2) 1.1 (−1.9, 4.2) 0.34 0.431
 Hormone replacement therapy 49 34.8 (28.6) 34.7 (27.0) 39 28.3 (19.7) 26.3 (17.8) 5.8 (−6.5, 18.0) 0.70 0.331
 Clonidine 49 0.5 (1.8) 0.5 (2.0) 39 0.2 (0.5) 0.4 (2.0) 0.1 (−1.0, 1.2) 0.13 0.908 b
 Tibolon 49 3.4 (4.1) 2.4 (2.7) 39 2.3 (2.8) 2.2 (3.4) −0.3 (−1.4, 0.8) 0.00 0.615
  1. The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
  2. n = number of practices
  3. aAdjusted difference between groups at end of intervention, corrected for baseline
  4. bstatistically significant interaction
  5. Misoprostol
  6. P 10: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
  7. P 90: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
  8. Triple therapy (ATC A02BD04)
  9. P10: B (95% CI): 0.9 (−0.2, 1.9). p: 0.117
  10. P90: B (95% CI):−0.4 (−1.6, 0.7). p: 0.413
  11. Antithyroid preparations
  12. P10: B (95% CI):−1.9 (−7.2, 3.4). p: 0.474
  13. P90: B (95% CI): 12.3 (4.6, 19.9). p: 0.002
  14. Clonidine
  15. P10: B (95% CI): 0.6 (−0.4, 1.6). p: 0.215
  16. P90: B (95% CI):−2.4 (−3.9,−1.0). p: < 0.001